Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Purchases 493,495 Shares of Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas purchased 493,495 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The shares were bought at an average price of $0.45 per share, for a total transaction of $222,072.75. Following the completion of the purchase, the chief executive officer directly owned 7,738,474 shares in the company, valued at $3,482,313.30. This represents a 6.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Monday, January 12th, Grigorios Siokas bought 113,185 shares of Cosmos Health stock. The shares were acquired at an average price of $0.50 per share, with a total value of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas acquired 156,190 shares of Cosmos Health stock. The shares were bought at an average cost of $0.52 per share, with a total value of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The stock was bought at an average price of $0.52 per share, for a total transaction of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas bought 133,953 shares of Cosmos Health stock. The stock was bought at an average cost of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were bought at an average cost of $0.49 per share, with a total value of $43,273.86.
• On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The stock was purchased at an average price of $0.42 per share, for a total transaction of $70,758.24.
• On Friday, November 28th, Grigorios Siokas acquired 76,360 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $48,870.40.
• On Tuesday, November 25th, Grigorios Siokas acquired 55,732 shares of Cosmos Health stock. The shares were purchased at an average price of $0.63 per share, with a total value of $35,111.16.
• On Friday, November 21st, Grigorios Siokas bought 56,080 shares of Cosmos Health stock. The stock was purchased at an average price of $0.68 per share, with a total value of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The shares were purchased at an average price of $0.62 per share, for a total transaction of $31,815.30.

Cosmos Health Stock Performance

NASDAQ COSM traded up $0.01 during trading hours on Thursday, hitting $0.45. 2,993,470 shares of the stock were exchanged, compared to its average volume of 1,138,761. Cosmos Health Inc. has a 12-month low of $0.28 and a 12-month high of $1.32. The stock has a 50-day moving average of $0.56 and a 200 day moving average of $0.73. The company has a market cap of $16.88 million, a price-to-earnings ratio of -0.60 and a beta of 5.37. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25.

Cosmos Health (NASDAQ:COSM) last issued its earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.16). The company had revenue of $17.11 million for the quarter, compared to analysts’ expectations of $16.40 million. Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%. As a group, equities research analysts forecast that Cosmos Health Inc. will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On Cosmos Health

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC boosted its holdings in Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 at the end of the most recent reporting period. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

Cosmos Health News Summary

Here are the key news stories impacting Cosmos Health this week:

• Positive Sentiment: Zacks Small‑Cap Research initiated coverage and assigned a $4.50 per share valuation, highlighting revenue growth, margin expansion, U.S. expansion (ZipDoctor, Sky Premium Life), AI-enabled R&D and a path to positive free cash flow — a catalyst for momentum in a thin‑market small cap. Article Title
• Positive Sentiment: CEO Grigorios Siokas has been actively buying shares (recent 113,185-share purchase disclosed), increasing insider ownership — a strong signal to investors that management is confident about near‑term prospects. Article Title
• Positive Sentiment: Institutional interest has ticked up (e.g., Citadel raised its stake in Q3 2025), which can support liquidity and reduce downside in small‑cap floats. Article Title
• Positive Sentiment: Zacks Small‑Cap’s forward EPS schedule models a movement from negative EPS in 2025–2026 to modestly positive EPS by FY2027, giving investors a clearer timeline for potential profitability improvement. Article Title
• Neutral Sentiment: Zacks’ valuation is DCF‑based using a high (20%) discount rate and the firm disclosed compensation from Cosmos for the report — useful visibility but raises questions about model assumptions and independence. Article Title
• Negative Sentiment: Recent GAAP results showed losses and a quarterly EPS miss (company reported negative margins and a negative ROE), underscoring execution and profitability risk that could limit upside until sustained improvements appear. Article Title
• Negative Sentiment: Small market cap, high beta and an average sell‑side rating (MarketBeat shows an overall “Sell” average) mean shares are volatile and speculative; any operational setbacks or marketwide risk aversion could push the stock lower. Article Title

Wall Street Analysts Forecast Growth

Several research firms have recently commented on COSM. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen upgraded Cosmos Health to a “hold” rating in a report on Saturday, September 20th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.